180 related articles for article (PubMed ID: 29651718)
1. The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis.
Dong C; Yuan Z; Li Q; Wang Y
Neurol Sci; 2018 Jul; 39(7):1191-1201. PubMed ID: 29651718
[TBL] [Abstract][Full Text] [Related]
2. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
3. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
Lu VM; Alvi MA; McDonald KL; Daniels DJ
J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
[TBL] [Abstract][Full Text] [Related]
4. H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients.
Vuong HG; Le HT; Ngo TNM; Fung KM; Battiste JD; McNall-Knapp R; Dunn IF
J Neurooncol; 2021 Dec; 155(3):225-234. PubMed ID: 34796414
[TBL] [Abstract][Full Text] [Related]
5. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
6. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
[TBL] [Abstract][Full Text] [Related]
7. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
8. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
Feng J; Hao S; Pan C; Wang Y; Wu Z; Zhang J; Yan H; Zhang L; Wan H
Hum Pathol; 2015 Nov; 46(11):1626-32. PubMed ID: 26297251
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
10. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
[TBL] [Abstract][Full Text] [Related]
11. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
Agarwal P; Aiyer HM
Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
[TBL] [Abstract][Full Text] [Related]
12. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
[TBL] [Abstract][Full Text] [Related]
13. Histone H3K27M Mutation Overrides Histological Grading in Pediatric Gliomas.
Mosaab A; El-Ayadi M; Khorshed EN; Amer N; Refaat A; El-Beltagy M; Hassan Z; Soror SH; Zaghloul MS; El-Naggar S
Sci Rep; 2020 May; 10(1):8368. PubMed ID: 32433577
[TBL] [Abstract][Full Text] [Related]
14. Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity.
Fischer NW; Prodeus A; Gariépy J
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089713
[TBL] [Abstract][Full Text] [Related]
15. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
[TBL] [Abstract][Full Text] [Related]
16. TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas.
Gillet E; Alentorn A; Doukouré B; Mundwiller E; van Thuijl HF; Reijneveld JC; Medina JA; Liou A; Marie Y; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Idbaih A
J Neurooncol; 2014 May; 118(1):131-9. PubMed ID: 24590827
[TBL] [Abstract][Full Text] [Related]
17. TP53 and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas.
Chan AK; Mao Y; Ng HK
N Engl J Med; 2016 Dec; 375(22):2206-2208. PubMed ID: 27959765
[No Abstract] [Full Text] [Related]
18. Histone H3 K27M mutations in adult cerebellar high-grade gliomas.
Nakata S; Nobusawa S; Yamazaki T; Osawa T; Horiguchi K; Hashiba Y; Yaoita H; Matsumura N; Ikota H; Hirato J; Yoshimoto Y; Yokoo H
Brain Tumor Pathol; 2017 Jul; 34(3):113-119. PubMed ID: 28547652
[TBL] [Abstract][Full Text] [Related]
19. Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas.
Pratt D; Natarajan SK; Banda A; Giannini C; Vats P; Koschmann C; Mody R; Chinnaiyan A; Venneti S
Acta Neuropathol; 2018 Feb; 135(2):299-301. PubMed ID: 29302777
[No Abstract] [Full Text] [Related]
20. Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis.
Enomoto T; Aoki M; Hamasaki M; Abe H; Nonaka M; Inoue T; Nabeshima K
Neurol Med Chir (Tokyo); 2020 Mar; 60(3):136-146. PubMed ID: 31902873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
